This article was originally published in The Gray Sheet
Executive SummaryBoard authorizes repurchase of up to 1 mil. shares of common stock. Separately, the Atlanta-based maker of human tissue implantable devices reported a 10% increase in third quarter revenues to $16 mil. Net income, excluding effects of the sale of the firm's Ideas for Medicine business, was up 31% to $1.9 mil. Including the sale, net income was up 118.7% to $3.2 mil
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.